Posted by Michael Wonder on 22 Jun 2017
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
22 June 2017 - Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan.
Genentech announced today that the U.S. FDA approved Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukaemia.
This new treatment includes the same monoclonal antibody as intravenous Rituxan (rituximab) in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin.
